DNA X, Inc.
For the period ended Mar 31, 2026. Filed May 20, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 20, 2026
SONM$2.22+4.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS EXCEPT SHARE AND PER SHARE AMOUNTS)
| March 31, 2026 | December 31, 2025 | |
|---|---|---|
| (Unaudited) | ||
| Assets | ||
| Cash and cash equivalents | $1,195 | $1,303 |
| Receivable for cash held back from the asset sale | 1,500 | — |
| Prepaid expenses and other current assets | 608 | 676 |
| Current assets held for sale | — | 26,930 |
| Total Current assets | 3,303 | 28,909 |
| Investment in DNA X LLC under equity method | 1,290 | 1,242 |
| Deferred tax assets | — | 1,441 |
| Other assets | 245 | 274 |
| Non-current assets held for sale | — | 12,032 |
| Total assets | $4,838 | $43,898 |
| Liabilities and stockholders’ deficit | ||
| Accounts payable | 719 | 4,030 |
| Accrued liabilities | 1,576 | 704 |
| Promissory note, net from related party | 1,072 | 1,035 |
| Promissory notes, net | — | 4,030 |
| Derivative liability | 398 | 171 |
| Income tax payable | 556 | 2,598 |
| Current liabilities held for sale | — | 38,057 |
| Total current liabilities | 4,321 | 50,625 |
| Deferred tax liability | 600 | — |
| Total liabilities | 4,921 | 50,625 |
| Commitments and contingencies (Note 9) | — | — |
| Redeemable common stock; $0.001 par value; 223,201 shares issued and outstanding; redemption value $900 at March 31, 2026 and $1,228 as of December 31, 2025 (Note 6) | 900 | 1,228 |
| Stockholders’ deficit | ||
| Common stock, $0.001 par value per share; 1,000,000,000 shares authorized: and 1,265,067 shares issued and outstanding at both March 31, 2026 and December 31, 2025* | 1 | 1 |
| Preferred stock, $0.001 par value per share, 5,000,000 shares authorized: and no shares issued and outstanding at March 31, 2026 and December 31, 2025 | — | — |
| Additional paid-in capital* | 296,613 | 296,309 |
| Accumulated deficit | (297,597) | (304,265) |
| Total stockholders’ deficit | (983) | (7,955) |
| Total liabilities, redeemable common stock, and stockholders’ deficit | $4,838 | $43,898 |
| * | Adjusted retroactively to reflect the 1-for-18 reverse stock split that became effective on October 28, 2025, see Note 1. |
|---|
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.